Paweł Wiśniewski
Paweł Wiśniewski has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Andrzej Jakubczyk
Department of Psychiatry, Medical University of Warsaw, Warsaw, Poland
1 shared publication- Andrzej Jakubczyk
Department of Psychiatry, Medical University of Warsaw, Nowowiejska 27, Warszawa, 00-665, Poland
1 shared publication Elisa M. Trucco
Department of Psychology, Center for Children and Families, Florida International University, Miami, FL, USA; Department of Psychiatry, Addiction Center, University of Michigan, Ann Arbor, MI, USA
1 shared publication- Elisa M. Trucco
Department of Psychology, Florida International University, 11200 SW 8th Street, Miami, FL 33199, USA
1 shared publication Hubert Suszek
Department of Psychology, University of Warsaw, Warsaw, Poland
1 shared publication- Hubert Suszek
Faculty of Psychology, University of Warsaw, Warsaw, Poland
1 shared publication
Latest Publications
- Open Access
Double-blind, placebo-controlled randomised clinical trial on flexible doses of escitalopram and naltrexone in the treatment of men with compulsive sexual behaviour disorder: study protocol presentation
Background Recent research has led to a better understanding of biological and psychosocial correlates of compulsive sexual behaviour disorder (CSBD). Psychotherapy is considered a first-line treatment strategy, while evidence on the use of pharmacotherapy is still scarce. This study aimed to provide new data on the efficacy of a selective serotonin reuptake inhibitor and an opioid receptor antagonist used as monotherapy or in combination in CSBD. Methods and analysis 410 adult men seeking treatment due to perceived loss of control over sexual behaviour and its negative consequences, meeting the ICD-11 diagnostic guideline of CSBD and scoring ≥50 on the Compulsive Sexual Behavior Disorder Scale, used for assessment of CSBD according to ICD-11 guidelines (CSBD-19) questionnaire, will be randomised to 24-week, double-blind treatment with either escitalopram 10–20 mg, naltrexone 25–50 mg, combined treatment or placebo (fixed- and flexible-dosing for the first and subsequent 12 weeks, respectively) with a 12-month follow-up after completing the medication. Men with relevant psychiatric or neurological comorbidity or cognitive impairment, with current psychoactive substance dependence or compulsive gambling, already using psychotropic medications, with positive drug test or significant blood lab test abnormality, or any medical or concomitant treatment-related contraindications for use of any of the investigated medications will be excluded from participation in this clinical trial. Patients will be assessed using structured clinical interviews, validated questionnaires, ecological momentary assessment and functional electroencephalography. Pharmacovigilance and lab tests will be provided throughout the active treatment phase to monitor its safety and tolerability. Main outcome measure will include changes in the severity of symptoms of compulsive sexual behaviours operationalised using CSBD-19 and Brief Pornography Screen (BPS) questionnaires as well as diary assessments. A mixed multivariate analysis of variance (MANOVA) model will be applied with three measurements (before therapy initiation, after 12—primary endpoint and 23 weeks of treatment—secondary endpoint) in the four treatment arms. Regression models will be used in the search of predictors of clinical outcomes and correlation analyses to measure the relationship between psychometric outcomes, diary variables and neuronal biomarkers. Ethics and dissemination Ethical approval was granted as part of the Clinical Trials Information System (CTIS) Part II assessment in Poland on 17 February 2025. The trial was authorised in Poland on 24 February 2025 (EU CT approval reference: 2024-514490-22-01). The results of the study will be presented during conferences and published in peer-reviewed journals. Trial registration number EUCT: 2024-514490-22-01.
Open AccessDouble-blind, placebo-controlled randomised clinical trial on flexible doses of escitalopram and naltrexone in the treatment of men with compulsive sexual behaviour disorder: study protocol presentation
Background Recent research has led to a better understanding of biological and psychosocial correlates of compulsive sexual behaviour disorder (CSBD). Psychotherapy is considered a first-line treatment strategy, while evidence on the use of pharmacotherapy is still scarce. This study aimed to provide new data on the efficacy of a selective serotonin reuptake inhibitor and an opioid receptor antagonist used as monotherapy or in combination in CSBD. Methods and analysis 410 adult men seeking treatment due to perceived loss of control over sexual behaviour and its negative consequences, meeting the ICD-11 diagnostic guideline of CSBD and scoring ≥50 on the Compulsive Sexual Behavior Disorder Scale, used for assessment of CSBD according to ICD-11 guidelines (CSBD-19) questionnaire, will be randomised to 24-week, double-blind treatment with either escitalopram 10–20 mg, naltrexone 25–50 mg, combined treatment or placebo (fixed- and flexible-dosing for the first and subsequent 12 weeks, respectively) with a 12-month follow-up after completing the medication. Men with relevant psychiatric or neurological comorbidity or cognitive impairment, with current psychoactive substance dependence or compulsive gambling, already using psychotropic medications, with positive drug test or significant blood lab test abnormality, or any medical or concomitant treatment-related contraindications for use of any of the investigated medications will be excluded from participation in this clinical trial. Patients will be assessed using structured clinical interviews, validated questionnaires, ecological momentary assessment and functional electroencephalography. Pharmacovigilance and lab tests will be provided throughout the active treatment phase to monitor its safety and tolerability. Main outcome measure will include changes in the severity of symptoms of compulsive sexual behaviours operationalised using CSBD-19 and Brief Pornography Screen (BPS) questionnaires as well as diary assessments. A mixed multivariate analysis of variance (MANOVA) model will be applied with three measurements (before therapy initiation, after 12—primary endpoint and 23 weeks of treatment—secondary endpoint) in the four treatment arms. Regression models will be used in the search of predictors of clinical outcomes and correlation analyses to measure the relationship between psychometric outcomes, diary variables and neuronal biomarkers. Ethics and dissemination Ethical approval was granted as part of the Clinical Trials Information System (CTIS) Part II assessment in Poland on 17 February 2025. The trial was authorised in Poland on 24 February 2025 (EU CT approval reference: 2024-514490-22-01). The results of the study will be presented during conferences and published in peer-reviewed journals. Trial registration number EUCT: 2024-514490-22-01.
- 1 December 2021
- Published by Elsevier in Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Vol. 111, 110397
Alcohol use and interoception – A narrative review
- 1 December 2021
- Published by Elsevier in Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Vol. 111, 110397
Alcohol use and interoception – A narrative review
- Open Access
- 23 March 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (6) , 1321
Pain Sensitivity, Negative Affect, and Alcohol Use Disorder Status: A Moderated Mediation Study of Emotion Dysregulation
Previous work suggests that the association between pain and emotional processes among individuals with alcohol use disorder (AUD) may differ from healthy controls. This study investigates whether pain sensitivity mediates the association between negative affect and emotional dysregulation and whether this association differs across AUD status using moderated mediation. The sample included 165 individuals diagnosed with AUD and 110 healthy controls. Of interest was pain sensitivity, as assessed with the Pain Sensitivity Questionnaire, negative affect, as assessed with the Beck Depression Inventory, and emotional dysregulation, as assessed with the Difficulties in Emotional regulation Scale. Age, biological sex, and current pain severity were included as covariates. The results support a moderated partial mediation model that explained 44% of the variance in emotional dysregulation. The findings indicate that negative affect is related to higher pain sensitivity across groups. Moreover, pain sensitivity partially mediated the association between negative affect and emotional dysregulation, but in opposite directions depending on AUD status. Among healthy controls, greater pain sensitivity was related to better emotional regulation, while greater pain sensitivity led to greater emotional dysregulation among individuals with AUD. The potential parallels in the underlying neurobiological mechanisms of emotionality, pain, and AUD suggest that interventions targeting pain may improve adaptive affect regulation skills, which in turn could reduce negative affect and its effect on pain sensitivity among individuals with AUD.
- 23 March 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (6) , 1321
Open AccessPain Sensitivity, Negative Affect, and Alcohol Use Disorder Status: A Moderated Mediation Study of Emotion Dysregulation
Previous work suggests that the association between pain and emotional processes among individuals with alcohol use disorder (AUD) may differ from healthy controls. This study investigates whether pain sensitivity mediates the association between negative affect and emotional dysregulation and whether this association differs across AUD status using moderated mediation. The sample included 165 individuals diagnosed with AUD and 110 healthy controls. Of interest was pain sensitivity, as assessed with the Pain Sensitivity Questionnaire, negative affect, as assessed with the Beck Depression Inventory, and emotional dysregulation, as assessed with the Difficulties in Emotional regulation Scale. Age, biological sex, and current pain severity were included as covariates. The results support a moderated partial mediation model that explained 44% of the variance in emotional dysregulation. The findings indicate that negative affect is related to higher pain sensitivity across groups. Moreover, pain sensitivity partially mediated the association between negative affect and emotional dysregulation, but in opposite directions depending on AUD status. Among healthy controls, greater pain sensitivity was related to better emotional regulation, while greater pain sensitivity led to greater emotional dysregulation among individuals with AUD. The potential parallels in the underlying neurobiological mechanisms of emotionality, pain, and AUD suggest that interventions targeting pain may improve adaptive affect regulation skills, which in turn could reduce negative affect and its effect on pain sensitivity among individuals with AUD.